drug · antibody
sarilumab
Phase 2updated 5mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and immune system disease and 10 investigational indications.
indications
indications
Rheumatoid Arthritis
targets
Interleukin-6 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying sarilumab
- phase2Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
- phase2A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- phase2A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- phase2Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- phase2Phase 1b/2 Study of IV Sarilumab in Adult With RA
- phase2Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- phase1A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
- phase2A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that